Sedation is one of the most common CNS adverse effects of opioid therapy and is mediated by μ receptor activation in the thalamus, locus coeruleus, and reticular activating system, producing decreased arousal and vigilance.¹ At therapeutic doses, sedation ranges from mild drowsiness to significant cognitive blunting; at supratherapeutic concentrations it progresses to obtundation and coma. Sedation typically shows partial tolerance with continued dosing, and most patients on stable long-term opioid therapy report meaningful improvement in alertness over days to weeks, but this tolerance is incomplete and never fully resolves, particularly for cognitively demanding tasks. Clinically, sedation is most problematic at initiation of therapy and after dose escalation; patients should be counseled against driving or operating heavy machinery until they have demonstrated stable alertness on their current dose. Psychostimulants such as methylphenidate and modafinil have been used in palliative care settings to counter opioid-induced sedation in patients for whom dose reduction is not possible, though evidence from randomized trials is limited.¹

Cognitive impairment from opioids spans a spectrum from mild attention and memory difficulties to frank delirium. Acute opioid administration impairs working memory, executive function, and psychomotor speed through μ receptor effects on prefrontal cortical and hippocampal circuitry.¹

Chronic opioid therapy is associated with persistent cognitive deficits in some patients, though separating opioid effects from those of chronic pain, comorbid depression, and sleep disturbance is methodologically challenging. Delirium is a particularly serious CNS complication that occurs most commonly in the elderly, in patients with underlying cognitive impairment, and in the context of toxic metabolite accumulation (notably M3G from morphine and H3G from hydromorphone in renal failure). The neuroexcitatory metabolite mechanism, specifically antagonism of glycine and gamma-aminobutyric acid type A (GABA-A) receptors by M3G and H3G, produces a characteristic picture of agitated delirium, myoclonus, allodynia, and in severe cases seizures; this presentation is not reversed by naloxone because it is not opioid-receptor-mediated, and the correct intervention is cessation of the offending opioid and rotation to a renally appropriate agent.¹

Euphoria, the intensely pleasurable subjective state produced by opioid μ receptor activation in mesolimbic circuits, is the primary neurobiological driver of opioid misuse and addiction. As reviewed in Module 1, opioids disinhibit dopamine neurons in the ventral tegmental area by suppressing GABAergic interneurons, producing a surge of dopamine release in the nucleus accumbens that constitutes the reward signal.² The magnitude of euphoria correlates with the speed of CNS opioid delivery: rapid IV or intranasal delivery produces greater euphoria than slow oral absorption, which is the pharmacokinetic rationale for abuse-deterrent extended-release formulations and for the lower abuse liability of oral opioids compared to injectable preparations of the same drug. Tolerance to euphoria develops relatively rapidly with repeated dosing, driving dose escalation in individuals with opioid use disorder. Patients receiving opioids for legitimate pain management report substantially less euphoria than opioid-naive individuals using opioids recreationally, possibly because pain itself partially antagonizes the hedonic effects of opioid activation, though this does not mean that pain patients are immune to developing opioid use disorder.²

Miosis results from μ receptor activation in the Edinger-Westphal nucleus of the oculomotor complex, producing parasympathetic constriction of the pupillary sphincter.¹ Unlike most opioid CNS effects, miosis does not substantially tolerize with chronic use, making it one of the most reliable clinical signs of opioid effect throughout the course of long-term therapy. Pinpoint pupils (1–2 mm) in the context of decreased consciousness and respiratory depression constitute the classic opioid toxidrome and are a critical bedside diagnostic finding. The absence of miosis in an obtunded patient should prompt consideration of other causes or of co-ingestion with agents that cause mydriasis (e.g., cocaine, anticholinergics), which can mask opioid-induced pupillary constriction. Miosis per se requires no treatment; it is a diagnostic sign, not an adverse effect requiring intervention.

Cough suppression is a therapeutic application of opioid activity in the nucleus tractus solitarius and cough centers in the brainstem, where μ and κ receptor activation raises the cough threshold.¹ Codeine and hydrocodone are the most commonly used opioid antitussives at subanalgesic doses. Dextromethorphan, a morphinan derivative with N-methyl-D-aspartate (NMDA) receptor antagonist and sigma receptor activity but minimal opioid receptor affinity at standard doses, is widely used as a non-opioid antitussive. The antitussive effect of opioids does not require analgesia-level dosing and develops at lower plasma concentrations; the clinical implication is that opioids used primarily for analgesia will suppress cough as a secondary effect, which can impair airway clearance in patients with pulmonary disease or postoperative risk for atelectasis.

Truncal rigidity (wooden chest syndrome) is an unusual but potentially life-threatening adverse effect seen primarily with high-dose rapid IV administration of potent opioids, particularly fentanyl, sufentanil, and alfentanil.¹ The mechanism involves μ receptor activation in striatal and brainstem motor circuits producing intense sustained contraction of thoracic and abdominal musculature, which markedly increases chest wall stiffness and can prevent effective bag-mask ventilation. It is most commonly encountered during rapid sequence induction of anesthesia with high-dose fentanyl or in the setting of inadvertent rapid infusion. Treatment is neuromuscular blockade (succinylcholine or a non-depolarizing agent) and airway management; naloxone may partially reverse the rigidity but is less reliable and slower than neuromuscular blockade in this acute setting. Awareness of this complication is important for any clinician involved in procedural sedation or anesthesia.¹

Opioid-induced hyperalgesia (OIH) is a paradoxical state in which opioid exposure produces increased sensitivity to painful stimuli, meaning that opioids cause the very phenomenon they are intended to treat.³ OIH is mechanistically distinct from tolerance (which is reduced analgesic effect at a given dose) and can be distinguished clinically by the observation that dose escalation worsens pain rather than improving it, and that reduction of the opioid dose paradoxically improves pain. The neurobiological mechanisms of OIH include central sensitization through NMDA receptor activation by glutamate released during opioid-induced synaptic activity; upregulation of spinal dynorphin, which activates pronociceptive pathways; descending facilitation from the rostral ventromedial medulla; and neuroinflammatory changes in spinal glia.³ OIH has been most consistently demonstrated with remifentanil in clinical studies but occurs with all opioids at sufficient doses and duration. Clinically, OIH should be considered in any patient on long-term opioid therapy whose pain worsens without an obvious new nociceptive source, particularly if the pain becomes more diffuse, hyperalgesic, or allodynic in character. Management includes dose reduction, opioid rotation, and addition of NMDA receptor antagonists such as ketamine or methadone, which may attenuate the central sensitization component.³

The cardiovascular effects of opioids are generally modest in normovolemic patients at therapeutic doses, which distinguishes them favorably from many other analgesic and sedative agents in acute care settings.¹ Most opioids produce mild bradycardia through vagotonic mechanisms, specifically increased parasympathetic tone from brainstem μ receptor activation, with remifentanil and alfentanil producing the most pronounced bradycardia among the fentanyl congeners. In patients with pre-existing sinus node dysfunction or on concomitant negative chronotropic agents (beta-blockers, calcium channel blockers, digoxin), this vagotonic effect can produce clinically significant bradycardia. Morphine and meperidine cause histamine release from mast cells through a non-immune direct degranulation mechanism; rapid IV administration can produce vasodilation, urticaria, flushing, and hypotension that is often misclassified as an allergic reaction.¹ This effect is rate-dependent and can be substantially attenuated by administering the drug slowly (over 15–30 minutes for morphine IV in non-emergency settings), by premedication with antihistamines, or by choosing a non-histamine-releasing alternative. Orthostatic hypotension can occur with opioids in volume-depleted patients or those on antihypertensive therapy, particularly with the first dose; patient counseling about fall risk is appropriate at opioid initiation.

Methadone occupies a unique position among opioids for its dose-dependent QTc prolongation through blockade of cardiac hERG (IKr) potassium channels.⁵ This is a pharmacological effect of the methadone molecule itself, independent of its opioid receptor activity, and is shared by both enantiomers. QTc prolongation is dose-dependent and additive with other QTc-prolonging agents; the clinical risk, namely torsades de pointes, a potentially fatal polymorphic ventricular tachycardia, is greatest when methadone plasma concentrations are elevated by CYP3A4 (cytochrome P450 3A4) inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors, grapefruit juice) or in patients with underlying long QT syndrome, hypokalemia, hypomagnesemia, or cardiac structural disease.⁵ Published guidelines from the American Pain Society and the American Heart Association recommend baseline 12-lead ECG before initiating methadone, repeat ECG at dose thresholds (typically at 30–40 mg/day and 100 mg/day total), and whenever clinically significant dose escalation occurs. A QTc interval greater than 500 ms warrants serious reassessment of the methadone regimen; intervals of 450–500 ms require close monitoring and electrolyte optimization. No other commonly used opioid produces clinically meaningful QTc prolongation at therapeutic doses.⁵

Urinary retention is a well-recognized opioid adverse effect mediated by μ receptor activation in the sacral spinal cord and detrusor muscle, increasing urethral sphincter tone and inhibiting the voiding reflex.¹ It occurs in approximately 25% of patients receiving neuraxial opioids (intrathecal or epidural) and less commonly with systemic opioids. Men with benign prostatic hyperplasia are at substantially increased risk. Urinary retention is managed with urinary catheterization; low-dose naloxone infusion has been used to reverse urethral retention without fully reversing analgesia, exploiting the differential sensitivity of opioid receptors in spinal vs. supraspinal circuits. Tamsulosin and other alpha-1 adrenergic antagonists are sometimes used prophylactically in at-risk patients receiving neuraxial opioids.

Neuroendocrine effects of chronic opioid therapy are clinically significant and substantially underrecognized in routine practice.⁷ Chronic μ receptor activation suppresses hypothalamic gonadotropin-releasing hormone (GnRH) pulsatility, producing hypogonadotropic hypogonadism, a state of secondary gonadal failure in which LH and FSH levels are low or inappropriately normal in the context of low sex steroid concentrations. In men, this manifests as reduced testosterone, decreased libido, erectile dysfunction, infertility, fatigue, depression, and accelerated bone loss (opioid-induced androgen deficiency [OPIAD]).⁷ In women, hypogonadotropic hypogonadism produces oligomenorrhea or amenorrhea, reduced libido, vaginal atrophy, impaired fertility, and accelerated bone loss. These effects occur at all opioid doses but are dose-dependent and more common with long-acting opioids and higher daily doses. Clinically, opioid-induced hypogonadism is underdiagnosed because its symptoms, including fatigue, sexual dysfunction, mood disturbance, and musculoskeletal pain, are often attributed to the underlying pain condition or to comorbid depression.⁷ Screening with morning total testosterone (men) or LH/FSH and estradiol (women) is warranted in patients on long-term opioid therapy who report these symptoms. Treatment options include dose reduction or opioid rotation (if feasible), and hormone replacement therapy for symptomatic patients if opioid discontinuation is not possible.

Adrenal insufficiency through suppression of the HPA axis (opioid-induced adrenal insufficiency [OIAI]) has been increasingly recognized; opioids reduce corticotropin-releasing hormone (CRH) and ACTH release, blunting cortisol production.⁷ Clinically, OIAI presents with fatigue, orthostatic hypotension, nausea, and hyponatremia, and may worsen under physiological stress. A morning cortisol or ACTH stimulation test is appropriate in patients on chronic high-dose opioids presenting with these features. Elevated prolactin levels are also a consistent finding with chronic opioid use, resulting from reduced dopaminergic inhibition of pituitary lactotrophs; in most patients this is asymptomatic but can contribute to galactorrhea or gynecomastia in susceptible individuals.⁷

Tolerance, physical dependence, and addiction are related but distinct phenomena that are frequently conflated in clinical practice and in public discourse, with significant consequences for patient care and for the stigmatization of patients with legitimate pain requiring opioid therapy.² Tolerance is defined as the reduction in pharmacological effect produced by a given dose of a drug following repeated exposure, requiring dose escalation to maintain the same effect.

Tolerance to opioids develops at different rates for different effects: tolerance to analgesia, sedation, nausea, and euphoria develops relatively rapidly over days to weeks; tolerance to respiratory depression develops somewhat more slowly; and tolerance to constipation and miosis develops minimally even with prolonged exposure.⁹ At the cellular and molecular level, tolerance results from receptor desensitization (G-protein-coupled receptor kinase (GRK)-mediated phosphorylation and β-arrestin uncoupling), receptor downregulation (decreased surface receptor density through persistent internalization), reduced G-protein coupling efficiency, upregulation of adenylyl cyclase (superactivation of cAMP signaling), and compensatory changes in downstream signaling pathways and ion channel expression.² Cross-tolerance, defined as reduced responsiveness to a different opioid due to tolerance to a prior opioid, is incomplete across opioids because different agents have different receptor occupancy profiles, binding kinetics, and signaling biases; this incomplete cross-tolerance is the pharmacological basis for dose reduction at opioid rotation, as described in Module 2.

Physical dependence is a neuroadaptive state in which the nervous system has adjusted its normal function to require the continued presence of the opioid; abrupt removal of the opioid produces a withdrawal syndrome representing unopposed expression of the upregulated opposing systems.⁹ The opioid withdrawal syndrome is characterized by a predictable constellation of autonomic, somatic, and affective symptoms: anxiety and dysphoria (from locus coeruleus noradrenergic hyperactivity and limbic system rebound), nausea, vomiting, diarrhea, abdominal cramping, diaphoresis, piloerection (goosebumps), lacrimation and rhinorrhea, myalgia, arthralgia, yawning, insomnia, and in severe cases hyperthermia and tachycardia.⁹

The onset and duration of withdrawal are determined by the half-life of the opioid: short-acting opioids (heroin, morphine, oxycodone) produce withdrawal beginning within 6–12 hours of the last dose, peaking at 36–72 hours, and resolving over 5–7 days; long-acting opioids (methadone) produce withdrawal with delayed onset (36–48 hours), gradual peak, and prolonged resolution over 2–3 weeks.⁹ Physical dependence is an expected pharmacological consequence of opioid exposure and is not synonymous with addiction; virtually all patients on scheduled opioid therapy for more than 2–3 weeks will develop physical dependence, and this does not imply that they have opioid use disorder or that their opioid use is problematic. Managed opioid tapering in a physically dependent patient does not precipitate the severe withdrawal seen with abrupt discontinuation; reductions of 10–20% of the total daily dose every 1–2 weeks are generally tolerable.

Antagonist-precipitated withdrawal, which involves abrupt displacement of opioid from receptors by administration of naloxone or naltrexone to a physically dependent patient, produces a severe, abrupt, and particularly distressing withdrawal syndrome that can be medically dangerous in debilitated patients. Opioid use disorder (OUD) is defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a problematic pattern of opioid use leading to clinically significant impairment or distress, characterized by loss of control over use, continued use despite adverse consequences, compulsive drug-seeking behavior, and neurobiological changes in reward, motivation, and executive control circuitry.²

OUD is a chronic relapsing brain disorder with a complex etiology involving genetic predisposition, adverse childhood experiences, psychosocial factors, and neurobiological vulnerability; it is not simply a matter of insufficient willpower or inadequate moral character. The mesolimbic dopamine system dysregulation underlying OUD is distinct from the physical dependence that accompanies prescribed opioid use; many patients on long-term opioid therapy for pain are physically dependent but do not have OUD, and this distinction matters for clinical communication, documentation, and the avoidance of stigmatizing language.² Risk factors for developing OUD with prescribed opioids include personal or family history of substance use disorder, history of major depression or post-traumatic stress disorder (PTSD), younger age, higher prescribed dose, longer duration of use, and concurrent benzodiazepine prescription. Evidence-based pharmacological treatment of OUD is addressed in the clinical applications section of Module 4.

Opioid antagonists are compounds that bind to opioid receptors with high affinity but produce no or minimal intrinsic receptor activation; they occupy the receptor and competitively displace agonists without triggering the downstream signaling that produces analgesic or other opioid effects.¹⁰ The three clinically available full opioid antagonists are naloxone, naltrexone, and nalmefene, all phenanthrene-derived agents; in addition, the peripherally restricted antagonists methylnaltrexone and naloxegol, which do not cross the blood-brain barrier, are used specifically for opioid-induced constipation without reversing central analgesia or precipitating systemic withdrawal. Naloxone (Narcan, Evzio, Kloxxado) is the primary agent for acute opioid overdose reversal and one of the most important drugs in emergency medicine and harm reduction.¹⁰

It is a pure competitive μ, κ, and δ receptor antagonist with particularly high μ receptor affinity. Naloxone has negligible intrinsic agonist activity and produces no discernible pharmacological effects in opioid-free individuals; its clinical effects are entirely a function of displacing opioid agonists from occupied receptors. Following IV administration, onset of action is within 1–2 minutes; IM or SC onset is 3–5 minutes; intranasal onset is 3–5 minutes via the concentrated 4 mg/0.1 mL formulation. The critical pharmacokinetic limitation of naloxone is its short duration of action: the elimination half-life is approximately 60–90 minutes, which is shorter than virtually all clinically significant opioids.¹⁰ This duration mismatch is the mechanistic basis for resedation (re-narcotization), in which a patient who responded to naloxone re-enters a state of opioid toxicity as naloxone is eliminated before the offending opioid has cleared.

Naloxone is available in multiple formulations designed for different clinical contexts: IV solution for hospital use; autoinjector (Evzio, 0.4 mg or 2 mg) for bystander community use; intranasal spray (Narcan 4 mg, Kloxxado 8 mg) as the dominant harm reduction distribution format; and as a fixed-dose combination with extended-release opioids (naloxone/oxycodone, OxyNeo in some jurisdictions) to deter parenteral abuse. FDA requirements for co-prescribing naloxone with opioids have expanded, and the FDA over-the-counter approval of intranasal naloxone (Narcan 4 mg) in 2023 removed prescription barriers for community access.¹⁰

Naltrexone (Vivitrol, ReVia) is a long-acting oral and injectable opioid antagonist used in the long-term pharmacological treatment of both opioid use disorder and alcohol use disorder.¹⁰ It is structurally similar to naloxone but is orally bioavailable (40–50%) and has a much longer half-life, approximately 4 hours for the parent compound and 13 hours for its active metabolite 6-β-naltrexol, providing approximately 24 hours of opioid receptor blockade per oral dose. Extended-release injectable naltrexone (Vivitrol, 380 mg IM monthly) provides consistent receptor blockade for approximately 30 days, eliminating the adherence challenges of daily oral dosing and the peaks and troughs in receptor occupancy associated with missed doses.¹⁰ Naltrexone is a pharmacological deterrent: patients who use opioids while on naltrexone experience no euphoria because opioids cannot activate occupied receptors. The clinical limitation of naltrexone is that it requires complete opioid detoxification before initiation: because it is a high-affinity antagonist, administration in an opioid-dependent patient will precipitate immediate severe withdrawal.¹⁰ Initiating naltrexone too soon after opioid cessation is a common and serious clinical error; for short-acting opioids, 7–10 days of abstinence is generally required; for methadone, 10–14 days may be insufficient, and provocative testing with a small naloxone dose before initiating naltrexone is prudent.

A critical safety concern with naltrexone is the loss of opioid tolerance during the period of receptor blockade: patients who relapse after discontinuing naltrexone have dramatically lower tolerance than before initiating the medication, placing them at very high risk of overdose death if they attempt to use opioids at previously tolerated doses.¹⁰

Nalmefene (Revex) is a pure opioid antagonist structurally similar to naltrexone with a half-life of approximately 8–9 hours, substantially longer than naloxone and making it useful for reversal of overdoses involving long-acting opioids where prolonged antagonism is desirable.¹⁰ Nalmefene is available parenterally in the United States for postoperative opioid reversal and overdose management. In Europe, a low-dose oral nalmefene formulation (Selincro) is approved for alcohol use disorder through its modulation of endogenous opioid signaling in reward circuits; this indication is not currently available in the United States.

Methylnaltrexone (Relistor) is a peripherally restricted quaternary ammonium derivative of naltrexone that does not cross the blood-brain barrier at therapeutic doses, providing selective antagonism of peripheral μ opioid receptors, particularly in the enteric nervous system, without reversing central analgesia or precipitating systemic opioid withdrawal.⁶ Subcutaneous methylnaltrexone is approved for opioid-induced constipation (OIC) in patients with advanced illness receiving palliative care when conventional laxative therapy has been inadequate, and an oral formulation is approved for OIC in adults with chronic non-cancer pain on long-term opioid therapy. Onset of laxation with SC methylnaltrexone is typically within 30–60 minutes in responsive patients. Naloxegol (Movantik) is a pegylated derivative of naloxone in which polyethylene glycol modification reduces CNS penetration; it is orally administered once daily and approved for OIC in adults with chronic non-cancer pain.⁶ Naldemedine (Symproic) is another orally administered peripherally acting mu-opioid receptor antagonist (PAMORA) approved for the same indication with a once-daily dosing schedule. All three agents should be used cautiously in patients with known or suspected GI obstruction, as restoration of propulsive motility in an obstructed bowel can cause perforation.⁶

Neuraxial opioid delivery, encompassing epidural and intrathecal routes, produces a distinct adverse effect profile that differs from systemic opioid administration in both the types and timing of complications, and requires specific clinical knowledge for safe management. The high analgesic potency of neuraxial opioids (achieving equivalent analgesia at doses 10- to 1,000-fold lower than systemic doses, depending on the opioid and route) does not eliminate systemic adverse effects; it modifies their incidence, timing, and clinical character in ways that can be counterintuitive.¹³

Delayed respiratory depression following intrathecal morphine is the most feared and clinically consequential adverse effect of neuraxial opioid administration. It arises through a mechanism distinct from the immediate respiratory depression seen with IV opioids: morphine, being hydrophilic (low lipid solubility), diffuses poorly into spinal cord tissue and instead remains dissolved in the CSF, where it undergoes slow rostral transport over hours. As morphine reaches the brainstem, specifically the pre-Botzinger complex (the medullary respiratory rhythm generator) and the nucleus tractus solitarius, it activates mu-opioid receptor (MOR) in these respiratory control centers and produces progressive respiratory depression with onset typically 6–12 hours after intrathecal injection and occasionally as late as 18 hours.¹³ This delayed time course is clinically dangerous precisely because patients may appear adequately ventilated and be discharged from recovery or stepped down from intensive monitoring before the peak of respiratory depression occurs.

Risk factors for clinically significant delayed respiratory depression include: high intrathecal morphine dose; opioid-naive status; concomitant systemic opioid or sedative administration; obesity; obstructive sleep apnea (OSA); and age over 65 years. Institutional monitoring protocols for intrathecal morphine typically require respiratory rate, sedation level, and oxygen saturation (SpO2) assessment at minimum every 1–2 hours for 12–18 hours after injection. Continuous capnography is more sensitive for early detection of hypoventilation than pulse oximetry alone, particularly in patients receiving supplemental oxygen, who can maintain acceptable SpO2 despite rising arterial carbon dioxide tension (PaCO2). Naloxone must be immediately available for all patients receiving neuraxial morphine; treatment of delayed respiratory depression follows the same principles as acute opioid overdose reversal, with the important caveat that repeated or continuous naloxone dosing may be required due to the prolonged duration of action of intrathecal morphine compared to the shorter elimination half-life of naloxone.¹³

Lipophilic opioids such as epidural or intrathecal fentanyl and sufentanil distribute rapidly into spinal cord tissue and systemic circulation, producing a pharmacokinetic profile after neuraxial administration that is more similar to IV administration than to intrathecal morphine. Respiratory depression from neuraxial fentanyl occurs early (within 30–90 minutes of epidural administration) rather than late, and it does not last as long; clinically significant delayed respiratory depression from neuraxial fentanyl is uncommon. This pharmacokinetic behavior also means that epidural fentanyl provides less segmental specificity than epidural morphine: its systemic absorption contributes substantially to analgesia, and its analgesic duration is shorter.¹³

In the obstetrical setting, where neuraxial opioids are widely used for labor analgesia and for post-cesarean analgesia, the choice between morphine (longer duration, higher pruritus and nausea incidence, delayed respiratory depression risk) and fentanyl (shorter duration, faster onset, lower pruritus incidence, early rather than delayed respiratory risk) is made based on the clinical context and the duration of required analgesia. Patient-controlled epidural analgesia (PCEA) combines an epidural local anesthetic and opioid (most commonly bupivacaine or ropivacaine with fentanyl) as a background infusion with patient-activated demand boluses, providing dynamic analgesic titration that can accommodate variable pain intensity throughout the postoperative or labor period. PCEA is now standard of care for thoracic and major abdominal surgery, and for labor analgesia in obstetrics. Compared with continuous epidural infusion alone, PCEA allows patients to self-titrate within safe programmed limits, reduces total opioid consumption, and improves patient satisfaction.¹³

Clinicians managing patients on PCEA must understand that the epidural catheter itself carries risks including migration (intravascular or intrathecal), infection, and hematoma formation, and that regular assessment of epidural catheter position and neurological function is required throughout the infusion period.

Neuraxial opioids delivered via implanted intrathecal drug delivery systems (IDDS), which are programmable pumps implanted subcutaneously with a catheter tunneled to the intrathecal space, represent a specialized application for patients with refractory chronic pain or cancer pain who have either failed systemic therapy or require very high systemic doses that produce intolerable adverse effects. Intrathecal morphine via IDDS achieves equivalent analgesia at doses approximately 300-fold lower than oral morphine, dramatically reducing the systemic adverse effect burden. Ziconotide (Prialt), a synthetic conotoxin that blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn, is the only non-opioid agent specifically approved for intrathecal delivery and is an option for patients who cannot tolerate intrathecal opioids.¹³ IDDS management requires specialized training in intrathecal pharmacology, pump programming, and the recognition of catheter-tip granuloma, an inflammatory mass that can form at the catheter tip with prolonged intrathecal opioid infusion and can cause neurological compromise from spinal cord compression. Catheter-tip granuloma should be suspected in any patient with an IDDS whose pain is worsening without an obvious new nociceptive cause or who develops new neurological signs; MRI of the spine is the diagnostic study of choice.¹³